Polyrizon completes fourth and fifth U.S. site contracts for NASARIX allergy study
Polyrizon said it has completed contracting for the fourth and fifth U.S. clinical sites for NASARIX™ first-in-human allergy study, completing all five U.S. site contracts for the trial.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.